Superworth

Bioventus price to free cash flow BVS

Market value divided by free cash flow over the last twelve months, since 2022.

Today, Nov 2, 2026
11.7×
5-year median
24.9×
Against its 5-year history
19th
percentile: 0 is its lowest day, 100 its highest
5-year range
7.1× to 216×
Peer median
18.3×

Bioventus' price to free cash flow is 11.7× as of Nov 2, 2026.

That is below its 5-year median of 24.9×, lower than on 81% of days in the last 5 years.

Over that time it ranged from 7.1× in May 2026 to 216× in Jul 2024.

The median for 10 medical instruments and supplies stocks of a similar size is 18.3×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far11.7×7.1×13.6×
202511.5×11.0×29.8×
202429.7×29.7×216×
202338.6×29.0×45.4×
202261.9×42.7×68.9×

Against its peers

Companies in Medical - Instruments & Supplies nearest Bioventus' size, closest first, today.

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Bioventus

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.